Screener
Travere Therapeutics, Inc. TVTX Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 164,114 | 124,406 |
| Operating loss | (36,915) | (42,674) |
| Other income, net: | ||
| Interest income | 2,584 | 3,795 |
| Interest expense | (2,300) | (2,857) |
| Other (expense) income, net | (91) | 549 |
| Total other income, net | 193 | 1,487 |
| Loss from continuing operations before income tax | (36,722) | (41,187) |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s interest income?
- Travere Therapeutics, Inc. (TVTX) reported interest income of $2.58M in Q1 2026.
- How has Travere Therapeutics, Inc.'s interest income changed year-over-year?
- Travere Therapeutics, Inc.'s interest income decreased by 31.9% year-over-year, from $3.8M to $2.58M.
- What is the long-term trend for Travere Therapeutics, Inc.'s interest income?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s interest income has grown at a 58.9% compound annual growth rate (CAGR), from $1.99M to $12.72M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Travere Therapeutics, Inc.'s interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude